Search TKNO
Alpha Teknova, Inc.
Nasdaq · CIK 1850902
Last close8.99
Daily change+0.13 (1.47%)
10 Years gain-64.04%
Dividends TTM0
Dividend yield0.00%
Fundamental Analysis
TKNO · STANDARD
SIC 2835 · In Vitro & In Vivo Diagnostic Substances · Fiscal year end 1231
Fundamental
36.2Momentum
100.0Acceleration
94.8Confidence
91.0Annual Revenue6
Quarterly Revenue22
Annual CFO6
Balance SheetAvailable
RankingEligible
Score Breakdown
Growth5.8 / 25
Quality12.5 / 25
Capital Efficiency0.0 / 20
Balance Sheet13.0 / 15
Shareholder Economics0.0 / 10
Forward Indicators5.0 / 5
Signals
Gross margin expansionGross margin improved by 15.0499 percentage points.
Operating leverageOperating margin improved by 27.2958 percentage points.
ROIC expansionROIC improved by 7.4084 percentage points.
Key Metrics
Revenue Growth TTM15.04%OK
Revenue CAGR 3Y-0.73%OK
Gross Margin36.04%OK
Operating Margin-33.16%OK
FCF Marginn/aMISSING
FCF Growthn/aINSUFFICIENT_HISTORY
ROIC-18.64%OK
Incremental Operating Margin 3Y2,200.89%OK
Net Debt / CFOn/aNOT_MEANINGFUL
Diluted Share Growth 1Y0.4%OK
SBC / Revenuen/aMISSING
SBC / FCFn/aNOT_MEANINGFUL
Financial History
| Period | Revenue | Gross Profit | Operating Income | CFO | FCF | Gross Margin | Op Margin | FCF Margin | ROIC | Shares |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025 FY Dec 31, 2025 | $40.52M | $13.44M | -$16.98M | -$8.65M | -$9.79M | 33.17% | -41.9% | -24.17% | -21.99% | 53.48M |
| 2025 FY Dec 31, 2024 | $37.75M | $7.23M | -$26.15M | -$12.39M | -$13.52M | 19.16% | -69.27% | -35.81% | -30.32% | 46.75M |
| 2024 FY Dec 31, 2023 | $36.68M | $10.30M | -$35.56M | -$18.81M | -$26.75M | 28.07% | -96.94% | -72.91% | -36.39% | 31.82M |
| 2023 FY Dec 31, 2022 | $41.42M | $17.48M | -$49.66M | -$27.40M | -$55.55M | 42.19% | -119.89% | -134.11% | -53.31% | 28.08M |
| 2022 FY Dec 31, 2021 | $36.89M | $17.62M | -$12.01M | -$9.07M | -$28.95M | 47.76% | -32.55% | -78.46% | -23.96% | 16.09M |
Formula Trace
| Metric | Value | Formula | Status | Source |
|---|---|---|---|---|
| Revenue TTM | $44.00M | sum latest 4 fiscal quarters Revenue | OK | 0001193125-26-338178, 0001193125-25-272321 |
| Revenue Growth TTM | 15.04% | Revenue_TTM / Revenue_TTM_1Y_ago - 1 | OK | 0001193125-26-338178, 0001193125-25-272321 |
| Revenue CAGR 3Y | -0.73% | (Revenue_current / Revenue_3Y_ago)^(1/3) - 1 | OK | 0001850902-26-000002 |
| Revenue CAGR 5Y | 5.3% | (Revenue_current / Revenue_5Y_ago)^(1/5) - 1 | OK | 0001850902-26-000002 |
| Gross Profit CAGR 3Y | -8.38% | (GrossProfit_current / GrossProfit_3Y_ago)^(1/3) - 1 | OK | 0001850902-26-000002 |
| Operating Income Growth | n/a | OperatingIncome_current / OperatingIncome_prior_year - 1 | INSUFFICIENT_HISTORY | 0001193125-26-338178, 0001193125-25-272321 |
| FCF Growth | n/a | FCF_current / FCF_prior_year - 1 | INSUFFICIENT_HISTORY | derived |
| Revenue Growth Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Profit Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Operating Income Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| FCF Acceleration | n/a | 0.5*(Q0-Q1)+0.3*(Q1-Q2)+0.2*(Q2-Q3) | INSUFFICIENT_HISTORY | derived |
| Gross Margin | 36.04% | Gross Profit / Revenue | OK | 0001193125-26-338178, 0001193125-25-272321 |
| Operating Margin | -33.16% | Operating Income / Revenue | OK | 0001193125-26-338178, 0001193125-25-272321 |
| ROIC | -18.64% | NOPAT / Average Invested Capital | OK | 0001193125-26-338178, 0001193125-25-272321 |
| Net Debt / CFO | n/a | Net Debt / CFO | NOT_MEANINGFUL | 0001193125-26-338178 |
| Current Ratio | 4.49x | Current Assets / Current Liabilities | OK | derived |
| Cash / Debt | 1.32x | (Cash + Short-term Investments) / Total Debt | OK | 0001193125-26-338178 |
| Revenue per Diluted Share | $0.82 | Revenue / Diluted Shares | OK | 0001193125-26-338178, 0001193125-25-272321 |